Intraocular pressure change after injection of intravitreal dexamethasone (Ozurdex) implant in Korean patients.

Wungrak ChoiSung Eun ParkHyun Goo KangSuk Ho ByeonSung Soo KimHyoung Jun KohSungchul LeeGong Je SeongChan Yun KimMin Kim

Published in: The British journal of ophthalmology (2018)

The incidence of adverse IOP elevation requiring the prolonged use of IOP-lowering medication and surgical intervention after DEX implantation was significantly lower than the incidence reported in previous Western population-based studies. Intravitreal DEX injection may therefore be an effective and relatively safe treatment modality for ME in Asian patients.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
randomized controlled trial
peritoneal dialysis
prognostic factors
healthcare
vascular endothelial growth factor
low dose
high dose
adverse drug
patient reported
case control